This CX Programme is subject to change.
Peripheral Critical Ischaemia Challenges - Thursday, 18th April
Venue: Lower Main Auditorium
Time: 08:00 - 18:00
ilegx Part 1
| Chairing: | Cliff Shearman, Southampton, United Kingdom |
| Moderator: | Robert Hinchliffe, Bristol, United Kingdom |
08:00 - 08:08
Approaching critical limb ischemia from a population health point of view
| Speaker: | Barry Katzen, Miami, United States |
08:08 - 08:16
The geriatric patient in the age of modern endovascular treatment options
| Speaker: | Marianne Brodmann, Graz, Austria |
08:16 - 08:24
Management of critical limb ischaemia of the lower limbs: Guidelines according to international scientific experience
| Speaker: | Athanasios Giannoukas, Larissa, Greece |
08:24 - 08:36
Audience participation, discussion and polling
08:36 - 08:44
Pilot assessment of the angiosome concept by intraoperative fluorescence angiography after tibial bypass surgery
| Speaker: | Ulrich Rother, Erlangen, Germany |
08:44 - 08:52
GLobal Anatomical Staging System: Draft guidelines for chronic limb threatening ischaemia
| Speaker: | Michael Conte, San Francisco, United States |
08:52 - 09:00
Combination approach in below-the-knee lesions
| Speaker: | Michael Lichtenberg, Arnsberg, Germany |
09:00 - 09:12
Audience participation and discussion
09:12 - 09:20
How to reduce dissections below-the-knee: Techniques & devices
| Speaker: | Jos van den Berg, Lugano, Switzerland |
09:20 - 09:28
TOBA II BTK update
| Speaker: | Michael Lichtenberg, Arnsberg, Germany |
09:28 - 09:36
Audience participation and discussion
09:36 - 09:44
Extended limb salvage operations for threatened ischaemic limbs
| Speaker: | Enrico Ascher, New York, United States |
09:44 - 09:52
Determinants of long-term outcomes and costs in the management of critical limb ischaemia: A population-based cohort study
| Speaker: | Barry Katzen, Miami, United States |
09:52 - 10:00
Audience participation and discussion
Coffee and visit to hands-on workshops
Time: 10:00 - 10:30
Coffee Symposium: Below the knee symposium
Time: 10:03 - 10:28
| Chairing: | Marc Bosiers, Dendermonde, Belgium |
10:03 - 10:15
The pedal access approach
| Speaker: | Amine Chouiter, Neuchatel, Switzerland |
10:15 - 10:28
Multidisciplinary foot clinics, a pathway to limb salvage?
| Speaker: | Paul Moxey, London, United Kingdom |
Peripheral Arterial Podium 1st Session
| Chairing: | Gunnar Tepe, Rosenheim, Germany |
| Moderator: | Thomas Zeller, Bad Krozingen, Germany |
10:30 - 10:38
Podium 1st: First results of the MUST trial and further updates on the use of microbubbles in thrombolysis
| Speaker: | Kak Khee Yeung, Amsterdam, Netherlands |
10:38 - 10:46
Podium 1st: Angiography alone in the lower limb: First results comparing IVUS and angiography in the leg
| Speaker: | Konstantinos Stavroulakis, Münster, Germany |
10:46 - 10:54
Podium 1st: Intravascular lithoplasty: Study status (DISRUPT PAD II and III) and lessons learnt from a real-world registry
| Speaker: | Andrew Holden, Auckland, New Zealand |
10:54 - 11:06
Audience participation and discussion
11:06 - 11:14
Podium 1st: The case for treating aortoiliac occlusive disease with a covered device: Early experience with new balloon-expandable endoprosthesis
| Speaker: | Michele Antonello, Padua, Italy |
11:14 - 11:22
Podium 1st: DCB IDE below-the-knee six-month results with in-depth look at Rutherford 5 patients
| Speaker: | Patrick Geraghty, St. Louis, United States |
11:22 - 11:30
Podium 1st: Final results of preclinical study comparing drug delivery on 0.018" vs. 0.035" DCB platforms
| Speaker: | Andrew Holden, Auckland, New Zealand |
11:30 - 11:42
Audience participation and discussion
11:42 - 11:50
Podium 1st: Two-year data from the MIMICS-2 study
| Speaker: | Timothy Sullivan, Minneapolis, United States |
11:50 - 11:58
Podium 1st: ZILVERPASS study - final 12-month and preliminary 24-month results
| Speaker: | Marc Bosiers, Dendermonde, Belgium |
11:58 - 12:06
Audience participation and discussion
12:06 - 12:14
Podium 1st: Multivariate analysis of 2,400 patients using a drug-eluting stent - patency data
| Speaker: | Michael Dake, Tucson, United States |
12:14 - 12:22
Podium 1st: REPLACE study - heparin-bonded ePTFE graft vs. ePTFE graft
| Speaker: | Yann Gouëffic, Nantes, France |
12:22 - 12:30
Audience participation and discussion
Lunch and visit to hands-on workshops
Time: 12:30 - 13:30
ilegx Part 2
Medical therapy and drug coating
| Chairing: | Michael Edmonds, London, United Kingdom |
| Moderator: | Keith Harding, Cardiff, United Kingdom |
13:30 - 13:38
Survival after lower extremity revascularisation for critical limb ischaemia is better with high dose statins
| Speaker: | Marc Schermerhorn, Boston, United States |
13:38 - 13:46
COMPASS and VOYAGER PAD are trying to answer our open questions for secondary prophylactic treatment in patients with peripheral arterial disease
| Speaker: | Marianne Brodmann, Graz, Austria |
13:46 - 13:54
Will drug-coated balloons and stents significantly impact our treatment of critical limb ischaemia?
| Speaker: | Peter Schneider, Honolulu, United States |
13:54 - 14:02
Audience participation, discussion and polling
iWounds
14:02 - 14:10
Percutaneous transluminal lower limb angioplasty for ischaemic foot ulcers: Five-year experience
| Speaker: | Mohamed Cassim, Nawala, Sri Lanka |
Patients awareness of peripheral arterial disease and the use of ankle-brachial Index measurement
| Speaker: | Jakob Susteric, Ljubljana, Slovenia |
14:18 - 14:26
Audience participation and discussion
14:26 - 14:34
Adequate wound care after successful endovascular treatment, a keystone for success
| Speaker: | Marianne Brodmann, Graz, Austria |
14:34 - 14:42
Rutherford 6 wounds: The utility of multivessel revascularisation and inflow strategies
| Speaker: | Peter Schneider, Honolulu, United States |
14:42 - 14:54
Audience participation and discussion
14:54 - 15:02
Footwear technology for diabetic foot ulcer patients
| Speaker: | Sjef van Baal, ALMELO, Netherlands |
15:02 - 15:10
Impact of hyperbaric oxygen on more advanced, Wagner grade 3 and 4 diabetic foot ulcers - matching therapy to specific wound conditions
| Speaker: | William Ennis, Chicago, United States |
15:10 - 15:18
Diabetes medications: Impact on inflammation and wound healing
| Speaker: | John Lantis, New York, United States |
15:18 - 15:30
Audience participation and discussion
Tea and visit to hands-on workshops
Time: 15:30 - 16:00
Mini-symposium on arterial disease below the ankle
| Chairing: | Gunnar Tepe, Rosenheim, Germany |
| Moderator: | Trevor Cleveland, President BSIR, Sheffield, United Kingdom |
16:00 - 16:08
Indications and techniques for below-the-ankle angioplasty
| Speaker: | Roberto Ferraresi, Milan, Italy |
16:08 - 16:16
The place for distal bypasses in below-the-ankle treatment
| Speaker: | Eric Ducasse, Bordeaux, France |
16:16 - 16:24
Audience participation and discussion
Mini-symposium on the ischaemic renal foot and Charcot foot
16:24 - 16:32
Diabetic patients in renal failure high rates of morbidity and mortality
| Speaker: | Michael Edmonds, London, United Kingdom |
16:32 - 16:40
Pathophysiology of lower limb and dialysis
| Speaker: | Robert Hinchliffe, Bristol, United Kingdom |
16:40 - 16:48
Audience participation and discussion
16:48 - 16:56
Temporal association between the incidence of foot ulceration and the start of dialysis in diabetes mellitus
| Speaker: | Frances Game, Derby, United Kingdom |
16:56 - 17:04
Chronic kidney disease as a predictor of outcome after revascularisation of the ulcerated diabetic foot
| Speaker: | Maarit Venermo, Helsinki, Finland |
17:04 - 17:12
Understanding the ischaemic Charcot foot patient
| Speaker: | Michael Edmonds, London, United Kingdom |
17:12 - 17:24
Audience participation and discussion
17:24 - 17:32
Surgical reconstruction of Charcot foot
| Speaker: | Venu Kavarthapu, London, United Kingdom |
17:32 - 17:40
Bypass outcomes where no autologous vein available
| Speaker: | Robert Hinchliffe, Bristol, United Kingdom |
17:40 - 17:48
Perineural local anaesthetic catheter after major lower limb amputation trial (PLACEMENT): Results from a multicentre randomised-controlled feasibility trial
| Speaker: | Graeme Ambler, Bristol, United Kingdom |
17:48 - 18:00
Audience participation and discussion